[{"indications": "Indications\u00a0treatment of acute migraine", "name": "ELETRIPTAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.4 Antimigraine drugs", "4.7.4.1 Treatment of acute migraine", "5HT1-receptor agonists", "ELETRIPTAN"], "cautions": "Cautions\u00a0see under 5HT1-receptor agonists above; interactions: Appendix 1 (5HT1 agonists)", "side-effects": "Side-effects\u00a0 see under 5HT1-receptor\r\nagonists above; also abdominal pain, dry mouth, dyspepsia;\r\ntachycardia, palpitation; drowsiness, headache; pharyngitis, rhinitis,\r\nchills; myasthenia, myalgia; sweating; less commonly diarrhoea, glossitis, thirst, anorexia, taste disturbance; dyspnoea,\r\nyawning, oedema, agitation, confusion, euphoria, depression, insomnia,\r\ndepersonalisation, tremor, dysarthria, stupor, movement disorders,\r\nhypertonia, urinary frequency, arthralgia, photophobia, visual disturbances,\r\ntinnitus, rash, and pruritus; rarely constipation,\r\noesophagitis, bradycardia, asthma, syncope, lymphadenopathy, and menorrhagia;\r\nischaemic colitis and hypertension also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106532.htm", "doses": ["adult over 18 years, 40\u00a0mg\r\nrepeated after 2 hours if migraine recurs (patient not responding\r\nto initial dose should not take second dose for same attack); increase\r\nto 80\u00a0mg for subsequent attacks if 40-mg dose inadequate; max. 80\u00a0mg\r\nin 24 hours"], "pregnancy": "Pregnancy\u00a0\n(From 5HT1-receptor agonists: British National Formulary)\nPregnancy\u00a0There is limited experience of using 5HT1-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk."}]